SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2017 / Cilt: 2 - Sayı: 2

One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation

Cem KESİM
Ali DEMİRCAN
Zeynep ALKIN
Korhan FAZIL
Abdullah ÖZKAYA
Mühittin TAŞKAPILI
Pages
62–66
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Five eyes received 1 PDT session and 3 eyes received 2 sessions.Conclusion: In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.Methods: A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted.
📊
Key Findings & Data:Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT.
💡
Conclusion & Impact:Five eyes received 1 PDT session and 3 eyes received 2 sessions.Conclusion: In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study was a comparison of the results achieved in patients with age-related macular degeneration and retinal angiomatous proliferation (RAP) diagnosis receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy and receiving photodynamic treatment (PDT) combined with anti-VEGF treatment.Methods: A retrospective chart review of patients with RAP who were treated in the retina clinic of Beyoglu Eye Training and Research Hospital was conducted. Patients were divided into 2 groups: patients who received anti-VEGF monotherapy formed Group I, and Group II comprised those who underwent combined therapy with PDT. Best corrected visual acuity (BCVA) and central macular thickness values at baseline and at months 6 and 12, and the number of anti-VEGF injections and PDT sessions were recorded.Results: Fifteen eyes of 14 patients were included. Six of the patients were female and 8 were male; the mean age was 73.2±9.7 years. The mean baseline BCVA was 0.70±0.52 log of the minimum angle of resolution. Visual acuity increased in 1 of 15 eyes (6.6%), remained stable in 10 eyes (66.6%), and decreased in 4 eyes (26.6%). A total of 7 eyes received anti-VEGF monotherapy, and 8 eyes received combined PDT and anti-VEGF treatment. The mean number of injections was 10.7±7.8. Five eyes received 1 PDT session and 3 eyes received 2 sessions.Conclusion: In this study, visual acuity was preserved in the majority of patients receiving anti-VEGF monotherapy and combined PDT and anti-VEGF treatment for RAP lesions

🔖

Cite This Article

KESİM, C., DEMİRCAN, A., ALKIN, Z., FAZIL, K., ÖZKAYA, A., TAŞKAPILI, M. (2017). One-Year Outcomes Comparison of Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation. BEYOGLU EYE JOURNAL, Cilt: 2 - Sayı: 2, 62–66. https://ajindex.com/articles/149395

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–72
  2. Yannuzzi LA, Negrão S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416–34
  3. Hunter MA, Dunbar MT, Rosenfeld PJ. Retinal angiomatous proliferation: clinical characteristics and treatment options. Optometry 2004;75:577–88
  4. Fernandes LH, Freund KB, Yannuzzi LA, Spaide RF, Huang SJ, Slakter JS, et al. The nature of focal areas of hyperfluorescence or hot spots imaged with indocyanine green angiography. Retina 2002;22:557–68
  5. Axer-Siegel R, Bourla D, Priel E, Yassur Y, Weinberger D. Angiographic and flow patterns of retinal choroidal anastomoses in age-related macular degeneration with occult choroidal neovascularization. Ophthalmology 2002;109:1726–36
  6. Bressler NM. Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol 2005;123:1741–3
  7. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 2004;138:1077–9
  8. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244:1224–32
  9. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541–60
  10. Kramann CA, Schöpfer K, Lorenz K, Zwiener I, Stoffelns BM, Pfeiffer N. Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmol 2012;90:487–91
  11. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009;247:1165–71
  12. Atmani K, Voigt M, Le Tien V, Querques G, Coscas G, Soubrane G, et al. Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye (Lond) 2010;24:1193–8
  13. Hemeida TS, Keane PA, Dustin L, Sadda SR, Faw